亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Stereotactic radiosurgery for brain metastasis from cholangiocarcinoma

放射外科 医学 脑转移 转移 放射科 癌症 内科学 放射治疗
作者
Ali Haluk Düzkalır,Yavuz Samancı,Cheng-chia Lee,Huai‐Che Yang,Ajay Niranjan,L. Dade Lunsford,Zhishuo Wei,Priyanka Srinivasan,Sam Dayawansa,Jason P. Sheehan,Samir Patel,David Mathieu,Brad E. Zacharia,Brandon Santhumayor,Douglas Kondziolka,Selçuk Peker
出处
期刊:Journal of Neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:: 1-8
标识
DOI:10.3171/2024.2.jns2483
摘要

OBJECTIVE Accounting for approximately 15% of primary liver cancers and 3% of gastrointestinal malignancies, cholangiocarcinoma (CCA) poses a serious health concern given its high mortality rate. Managing brain metastases (BMs) from CCA is challenging because of their rarity and poor prognosis, with little guidance on treatment from the literature. In this study, the authors aimed to evaluate the safety and efficacy of stereotactic radiosurgery (SRS) in managing BMs from CCA. METHODS This multicenter retrospective study included 13 CCA patients with 41 BMs treated with SRS from October 2006 to April 2022 at eight institutions affiliated with the International Radiosurgery Research Foundation. Inclusion criteria were a CCA diagnosis, an age over 18 years, no other malignancies, single-fraction SRS treatment for BMs, and at least one follow-up image. Data on demographics, tumor characteristics, treatment details, and outcomes were collected. The primary endpoints were local control (LC), intracranial progression-free survival (PFS), and overall survival (OS). The secondary endpoint was the development of adverse radiation effects (AREs). RESULTS The median radiological follow-up was 5 months (range 1–18 months). At the last follow-up, LC was achieved in 39 (95.1%) of 41 BMs. New distant metastases were observed in 3 patients (23.1%), and the mean intracranial PFS was 9.4 months (95% CI 6.5–12.3 months). Six-month and 1-year OS rates were 38.5% and 11.5%, respectively, and the median OS was 6 months (95% CI 4.9–7.2 months). Concurrent immunotherapy was associated with a high risk of local failure (HR 29.665, 95% CI 1.799–489.206, p = 0.018), and the absence of systemic chemotherapy before SRS was linked to reduced OS (HR 6.658, 95% CI 1.173–37.776, p = 0.032). Regarding AREs, only 1 patient (7.7%) experienced right hemiparesis and was treated with corticosteroid therapy. CONCLUSIONS SRS is an effective option for managing BMs in CCA patients, showing promise in LC and a high safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
兰乖乖完成签到,获得积分10
25秒前
团子完成签到 ,获得积分10
32秒前
jinzejin完成签到,获得积分10
32秒前
35秒前
嘻哈hang应助小小采纳,获得10
35秒前
兰乖乖发布了新的文献求助10
39秒前
40秒前
科研通AI2S应助科研通管家采纳,获得10
42秒前
俊逸的盛男完成签到 ,获得积分10
50秒前
复杂的鸡翅完成签到,获得积分10
1分钟前
liuda完成签到 ,获得积分10
1分钟前
1234发布了新的文献求助20
1分钟前
my完成签到 ,获得积分10
1分钟前
三十完成签到 ,获得积分10
1分钟前
Furmark_14完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Otter完成签到,获得积分10
1分钟前
GGGGD发布了新的文献求助10
1分钟前
LHS发布了新的文献求助20
1分钟前
默默琳完成签到,获得积分10
1分钟前
深情安青应助GGGGD采纳,获得10
1分钟前
GGGGD完成签到,获得积分10
2分钟前
春日奶黄包完成签到 ,获得积分10
2分钟前
2分钟前
merry991024完成签到,获得积分10
2分钟前
33给wang的求助进行了留言
2分钟前
张张发布了新的文献求助10
2分钟前
儒雅香彤完成签到 ,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
英俊的铭应助科研通管家采纳,获得10
2分钟前
Lucas应助张张采纳,获得10
2分钟前
znd完成签到 ,获得积分10
2分钟前
纯真的凝丝完成签到 ,获得积分10
2分钟前
Jun完成签到 ,获得积分10
3分钟前
3分钟前
sunqianxi完成签到,获得积分10
3分钟前
小孟吖完成签到 ,获得积分10
3分钟前
乐乐应助莫里亚蒂采纳,获得10
3分钟前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Востребованный временем 2500
Aspects of Babylonian celestial divination : the lunar eclipse tablets of enuma anu enlil 1500
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1040
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
지식생태학: 생태학, 죽은 지식을 깨우다 600
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3455618
求助须知:如何正确求助?哪些是违规求助? 3050848
关于积分的说明 9022941
捐赠科研通 2739402
什么是DOI,文献DOI怎么找? 1502781
科研通“疑难数据库(出版商)”最低求助积分说明 694586
邀请新用户注册赠送积分活动 693400